ImmunityBio Balance Sheet
NASDAQ: IBRXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
ImmunityBio financial position
At the end of fiscal 2025, ImmunityBio reported total assets of $501.9 million, up 31.1% from a year earlier against total liabilities of $1.00 billion. Shareholders' equity was negative at -$500.5 million, meaning liabilities exceed assets; this is often the result of large share buybacks or accumulated losses. The company held $88.3 million in cash and equivalents against $1.8 million of debt, a net cash position of $86.6 million.
The current ratio (current assets divided by current liabilities) was 5.10, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
ImmunityBio balance sheet (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 88.33M | 143.43M | 265.45M | 104.64M | 181.10M | 34.91M | 75.80M | 16.82M | 23.87M | 8.08M |
| Short-Term Investments | 154.48M | 6.38M | 1.01M | 2.54M | 136.01M | 61.15M | 36.14M | 57.33M | 104.28M | 190.84M |
| Receivables | 42.57M | 2.36M | 0 | — | — | — | — | — | — | — |
| Inventory | 910.00K | 8.27M | 0 | — | — | — | — | — | — | — |
| Total Current Assets | 314.88M | 184.59M | 294.08M | 140.58M | 334.35M | 111.71M | 55.76M | 88.77M | 132.46M | 205.15M |
| Property, Plant & Equipment | 114.26M | 137.09M | 146.08M | 143.66M | 82.86M | 72.54M | 60.50M | 76.89M | 76.73M | 18.91M |
| Goodwill | 910.00K | 910.00K | — | — | — | — | — | — | — | — |
| Intangible Assets | 12.99M | 14.53M | 17.09M | 20.00M | 1.42M | 1.46M | 0 | 565.00K | 2.83M | 5.09M |
| Long-Term Investments | — | 0 | 891.00K | 840.00K | 822.00K | 950.00K | 1.50M | 5.70M | 29.60M | 87.57M |
| Total Assets | 501.90M | 382.93M | 504.45M | 362.36M | 468.91M | 221.38M | 143.12M | 181.95M | 250.44M | 317.50M |
| Accounts Payable | — | — | — | 21.02M | 11.42M | 11.51M | 1.75M | 2.79M | 5.87M | 4.04M |
| Short-Term Debt | 1.75M | 1.25M | — | — | — | — | — | — | — | — |
| Total Current Liabilities | 61.75M | 54.94M | 58.28M | 500.86M | 369.00M | 68.13M | 11.56M | 27.26M | 20.87M | 12.55M |
| Total Liabilities | 1.00B | 871.06M | 1.09B | 812.18M | 712.82M | 339.87M | 22.44M | 35.94M | 31.60M | 24.08M |
| Shareholders' Equity | -500.47M | -489.10M | -586.99M | -447.33M | -242.17M | -119.81M | 120.68M | 146.01M | 218.84M | 293.42M |
| Retained Earnings | -3.73B | -3.38B | -2.96B | -2.38B | -1.96B | -1.62B | -662.19M | -594.98M | -498.71M | -387.06M |
| Total Debt | 1.75M | 1.25M | — | — | — | — | — | — | — | — |
| Net Cash (Debt) | 241.07M | 148.56M | 266.46M | 107.18M | 317.12M | 96.06M | 111.94M | 74.15M | 128.15M | 198.92M |
| Shares Outstanding | 1.01B | 852.90M | 670.87M | 421.57M | 397.83M | 382.24M | 98.46M | 79.09M | 79.02M | 81.98M |
This table shows 10 annual periods of ImmunityBio's balance sheet, from FY 2025 back to FY 2016, across 19 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow IBRX's reporting calendar. What is a balance sheet?